by Jordan Dietrich
SOLO3 is an exciting phase III ovarian cancer clinical trial that studies the effectiveness and safety of the PARP inhibitor Olaparib (Lynparza) compared to single-agent standard chemotherapy in women with platinum-sensitive relapsed ovarian cancer with germline BRCA1/2 mutations. The trial is designed to confirm the benefit of Olaparib in this subset of ovarian cancer patients.
The trial is based on promising results from earlier studies and the SOLO2 phase III clinical trial, which showed improvement of progression-free survival (PFS) in a subset of patients treated with Lynparza as maintenance therapy compared to placebo.
What is Lynparza?
Lynparza (also known as Olaparib) is a PARP inhibitor, a drug that targets cancers that have a reduced ability to repair DNA. In patients with BRCA mutations, PARP inhibition can preferentially kill cancer cells while sparing normal cells. Lynparza is being developed as a single-agent oral therapy as well as being studied in combination with other
therapies, such as immunotherapies.
Eligible patients will be randomly assigned to one of two groups: The Lynparza group or a standard chemotherapy group. Participants will have a two-out-of-three chance of being assigned to the Lynparza group. Those assigned to Lynparza will take tablets twice daily by mouth. Those assigned to the standard chemotherapy group will take a standard chemotherapy chosen by their physician (weekly paclitaxel, topotecan, pegylated liposomal doxorubicin, or gemcitabine).
Who is Eligible?
SOLO3 is open only to women with a BRCA mutation. Ovarian cancer survivors who have not previously had genetic testing can take a blood or saliva test to learn if they have a BRCA mutation. The study is open to women with relapsed high grade, serous ovarian cancer who have received at least two prior platinum-based lines of chemotherapy. Participants’ tumors must be at least partially platinum-sensitive. For more information, visit the SOLO3 website.
Jordan Dietrich is a clinical research associate in gynecologic oncology at Massachusetts General Hospital. He graduated from Tufts University in 2014 and is an aspiring physician.Tags: BRCA 1, BRCA 2, brca research, brca testing, BRCA2, HBOC, hereditary cancer, ovarian cancer early detection, ovarian cancer treatment